Articles

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma

Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Section of Animal and Human Physiology, National and Kapodestrian University of Athens, Department of Biology, School of Science, Athens
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Department of Paediatrics and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford
Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Department of Cellular and Molecular Pathology, Northwest London Pathology, Imperial College Healthcare NHS Trust, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom; Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Foundation Trust, London
Haematologica Early view Feb 18, 2021 https://doi.org/10.3324/haematol.2020.274480